Authors: Szczepankiewicz, BG Liu, G Jae, HS Tasker, AS Gunawardana, IW von Geldern, TW Gwaltney, SL Wu-Wong, JR Gehrke, L Chiou, WJ Credo, RB Alder, JD Nukkala, MA Zielinski, NA Jarvis, K Mollison, KW Frost, DJ Bauch, JL Hui, YH Claiborne, AK Li, Q Rosenberg, SH

Citation: Bg. Szczepankiewicz et al., New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models, J MED CHEM, 44(25), 2001, pp. 4416-4430

Authors: Boyd, SA Mantei, RA Tasker, AS Liu, G Sorensen, BK Henry, KJ von Geldern, TW Winn, M Wu-Wong, JSR Chiou, WJ Dixon, DB Hutchins, CW Marsh, KC Nguyen, E Opgenorth, TJ

Citation: Sa. Boyd et al., Discovery of a series of pyrrolidine-based endothelin receptor antagonistswith enhanced ETA receptor selectivity, BIO MED CH, 7(6), 1999, pp. 991-1002

Authors: Henry, KJ Wasicak, J Tasker, AS Cohen, J Ewing, P Mitten, M Larsen, JJ Kalvin, DM Swenson, R Ng, SC Saeed, B Cherian, S Sham, H Rosenberg, SH

Citation: Kj. Henry et al., Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity, J MED CHEM, 42(23), 1999, pp. 4844-4852

Authors: von Geldern, TW Tasker, AS Sorensen, BK Winn, M Szczepankiewicz, BG Dixon, DB Chiou, WJ Wang, LM Wessale, JL Adler, A Marsh, KC Nguyen, E Opgenorth, TJ

Citation: Tw. Von Geldern et al., Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity, J MED CHEM, 42(18), 1999, pp. 3668-3678

Authors: O'Connor, SJ Barr, KJ Wang, L Sorensen, BK Tasker, AS Sham, H Ng, SC Cohen, J Devine, E Cherian, S Saeed, B Zhang, HC Lee, JY Warner, R Tahir, S Kovar, P Ewing, P Alder, J Mitten, M Leal, J Marsh, K Bauch, J Hoffman, DJ Sebti, SM Rosenberg, SH

Citation: Sj. O'Connor et al., Second-generation peptidomimetic inhibitors of protein farnesyltransferasedemonstrating improved cellular potency and significant in vivo efficacy, J MED CHEM, 42(18), 1999, pp. 3701-3710